Destiny-breast01 nct03248492
WebJul 14, 2024 · Pooling data from August 2015 to June 2024 (61 patients participated in phase 1 studies DS8201-A-J101 [NCT02564900], and DS8201-A-A104 [NCT03383692], and 184 patients were in the phase 2 DESTINY-Breast01 study [NCT03248492]), including this update from ASCO, indicated that ILD occurred in 15.5% of patients with HER2 … WebFeb 15, 2024 · DESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2 positive metastatic breast cancer (MBC) and supported regulatory approval ...
Destiny-breast01 nct03248492
Did you know?
WebDec 20, 2024 · Efficacy was investigated in DESTINY-Breast01 (NCT03248492), a multicenter, single-arm trial enrolling 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had... WebDESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 registration study of T-DXd in subjects with centrally confirmed HER2-positive metastatic BC. Methods Part 1 of this 2-part study was performed in 2 stages (pharmacokinetics and dose finding; T-DXd 5.4, 6.4, 7.4
WebFeb 22, 2024 · A pooled safety analysis was based on 234 patients treated with at least one dose of Enhertu in DESTINY-Breast01 and in other studies, with a median duration of treatment of 9.8 months. The therapy was generally well-tolerated, with 33 treatment discontinuations (17.9% of patients) due to treatment-emergent side effects (adverse … WebFDA approval for Enhertu was based on the results of a multicenter, single-arm, clinical trial, DESTINY-Breast01 (NCT03248492), that enrolled 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. Patients were excluded for a history ...
Web转移性乳腺癌 试验背景. ds8201的疗效在destiny-breast01(nct03248492)研究中进行了评估,这是一项多中心、单臂的试验,纳入了184 ... WebMar 30, 2024 · In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3 ...
WebFeb 15, 2024 · Abstract. BackgroundTrastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2 positive …
WebMay 28, 2024 · On the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard … oracle and 和 orWebOn the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard treatments (Japan). portsmouth ri school districtWebNov 30, 2024 · Sara Hurvitz, MD:Before we discuss how this data should be implemented in our clinical practice, I'd like to discuss another poster that was presented at ESMO [European Society for Medical Oncology], the updated overall survival results from DESTINY-Breast01 [NCT03248492].Let’s talk about how you are using T-DXd in your … oracle and sql server comparisonWebMonthly Plenary Series . Abstracts & Presentations oracle andalsoWebJul 8, 2024 · Krop et al. conducted a phase 2 DESTINY-Breast01 (NCT03248492) study in which 253 patients with metastatic HER2-positive breast cancer previously treated with T-DM1 were included [3]. Median age of the patients was 55 years, 34.2% was Asian, 28.8% North American, and 37% European; 52.7% was HER2+ and 45.1% was HER2- (of … oracle and toadWebFeb 13, 2024 · In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.). oracle and orange grove wells fargoWebDec 2, 2024 · DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC).We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. oracle and sun microsystems merger